SEER INC. CL.A O.N.

Bradley L. Radoff and Michael Torok, holding about 7.7% of Seer, submitted a fourth non-binding takeover offer of $2.55 per share in cash, supplemented by a CVR that guarantees shareholders 85% of net proceeds from any future licensing or commercialization. The offer represents a 51% premium to the April 10, 2026 price and a 29% premium to last Monday’s closing price, is valid until August 10, 2026, and is not subject to a financing condition. The bidders criticize CEO Omid Farokhzad for prior capital losses and are pushing for an open auction process and cooperation with their financial adviser; only limited confirmatory due diligence is contemplated. » Plus sur de.investing.com

Proxy adviser Glass, Lewis & Co. recommends Seer shareholders vote for Howard H. Berman and Luis E. Rinaldini, and at the same time urges not to support Terrance McGuire and Dipchand Nishar. The recommendation is justified by ongoing operating losses, the stock’s underperformance since the IPO and an uncertain outlook for commercial scale-up. Glass Lewis views Berman and Rinaldini as complementary additions with external biotech operating experience and expertise in M&A, capital markets and transactions. The recommendation follows similar support from Institutional Shareholder Services and stems from the nomination by the Radoff-JEC Group. » Plus sur de.investing.com

Seer is urging shareholders to vote for its seven nominated board candidates at the annual meeting on July 28, 2026. Opponents Bradley Radoff and Michael Torok are seeking seats and, the board says, are pursuing an early sale of the company; the board criticizes the challengers’ lack of experience in proteomics and life-science tools. As of May 11, 2026, the board held about 17% of the outstanding shares; Seer has a market capitalization of USD 119 million, revenue of USD 15.17 million over the last twelve months and strong short-term liquidity. » Plus sur de.investing.com